Photo Credit: Kiley Klas
Inforce 3 is a MLV intranasal vaccine used for the prevention of respiratory disease caused by BRSV, and as an aid in preventing respiratory disease caused by IBR and PI3. Inforce 3 can be utilized in several different ways depending on when you administer the vaccine.
The advantage of using a MLV intranasal vaccine over a SQ or IM vaccine is the immune response for intranasal is faster. This means the calf/cow has protection shortly after vaccination, sometimes within a couple of days. The mucosal immune system is functional in newborn calves and can be accessed despite high levels of maternal antibody transfer. By using intranasal vaccination, antibodies can be produced on the mucosal surface in newborn calves providing protection from respiratory disease.1,2
Typical uses for Inforce 3 include vaccinating:
- Very young beef or dairy calves to induce early age respiratory protection. An injectable Virus/Mannheimia vaccine is typically given a couple of months later, and again at 6-8 months of age.
- Small calves in conjunction with One Shot BVD in the spring as a management practice to avoid summer pneumonia. Young calves can succumb quickly to summer pneumonia.
- In conjunction with One Shot BVD in a pre-conditioning program prior to weaning calves. These vaccinations can be very beneficial in preventing considerable future losses to respiratory disease.
- Calves on-arrival to starting lots to help induce rapid respiratory protection and local antibody production. An injectable Virus/Mannheimia vaccine is typically used on-arrival as well.
- Cattle on-arrival to feedlots in conjunction with One Shot BVD to help prevent bovine respiratory disease. An injectable Virus/Mannheimia vaccine is typically given 2 weeks later.
Using Inforce 3 provides fast and effective respiratory protection in several situations making it an ideal vaccine for any cattle operation.
1 D.A. Moore, Director of Veterinary Extension, Washington State University
A.J. Allen, College of Veterinary Medicine, Washington State University
2 Dr. Philip Griebel, DVM and research fellow with the vaccine and Infectious Disease Organization at the University of Saskatchewan